Table 2

Primary outcome measures used across randomised controlled trials for FND subgroups

FND symptomsPrimary outcome measures
Seizures (k=15)Core symptoms
  • Seizure frequency/occurrence (k=11)38–45 (S1 and S2) (Fobian NCT02801136).

Life impact
  • SF-36/QoLIE-31 (k=1) (Hingray NCT02311829).

  • WSAS (k=1).45

  • Treatment adherence/HCU (k=3) (S3 and S4) (Schommer NCT03329703).

Movement disorder (k=7)Core symptoms
  • PMDRS (k=4) or other FMD clinician rating scale (k=1) (S5–S9).

  • CGI-I (clinician) (k=1) (S10).

  • Unspecified (k=1) (S11).

Paralysis/weakness (k=4)Core symptoms
  • Subjective symptom severity ratings (k=1) (S12) or CGI-I (patient) (k=1) (Nicholson ISRCTN51225587).

  • Clinician-rated symptom severity (Chastan NCT01352910).

  • Dynamometry (k=1) (S13).

Life impact
  • Disability (SF-12, MRS, k=1) (S12).

Mixed motor symptoms (k=4)Core symptoms
Life impact
  • SF-36 Physical Functioning Scale (k=1) (S14).

  • Unspecified (k=1) (S15).

Other mixed symptoms (k=10)Core symptoms
  • Clinician-rated symptom severity (k=3) (S16–S18)

  • CGI-I (k=2, 1=clinician, 1=patient) (S19 and S20).

  • SDQ-20 (k=1) (S19).

  • Recovery (unspecified, k=1) (S21).

Life impact
  • SF-36 (k=1) (S22).

  • MRS (k=1) (S19).

  • Treatment adherence/HCU (k=1) (Bullock NCT02764476).

  • Interoception/attention tasks (k=1) (S23).

  • References S1-S23 are available in Supplementary File 7

  • CGI-I, Clinical Global Impression–Improvement; FMD, functional movement disorder; FND, functional neurological disorder; HCU, healthcare use; k, number of studies; MRS, Modified Rankin Scale; PMDRS, Psychogenic Movement Disorder Rating Scale; QoLIE-31, Quality of Life In Epilepsy-31; SDQ-20, Somatoform Dissociation Questionnaire-20 item; SF-12, 12-Item Short Form Health Survey; SF-36, 36-Item Short Form Health Survey; WSAS, Work and Social Adjustment Scale.